Xospata is a cancer medicine used to treat adults with acute myeloid leukaemia (AML), a cancer of white blood cells. Xospata is used when AML has either come back or has not improved following previous treatment and is only given to patients whose cancer cells have a particular change (mutation) in the gene for a protein called FLT3. The active substance in Xospata is gilteritinib. AML is rare, and Xospata was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 January 2018.
Therapeutic Indication
### Therapeutic indication Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.
Therapeutic Area (MeSH)
N/AATC Code
L01EX13
ATC Item
gilteritinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| gilteritinib fumarate | N/A | 吉瑞替尼 |
EMA Name
Xospata
Medicine Name
Xospata
Aliases
N/ANo risk management plan link.
